{
    "clinical_study": {
        "@rank": "90929", 
        "brief_summary": {
            "textblock": "The purpose of this study is to see if it is safe and effective to give indinavir sulfate\n      plus stavudine to HIV-infected patients who have already been treated with zidovudine."
        }, 
        "brief_title": "A Study of Indinavir Sulfate Given Together With Stavudine to HIV-Positive Patients", 
        "condition": "HIV Infections", 
        "condition_browse": {
            "mesh_term": [
                "HIV Infections", 
                "Acquired Immunodeficiency Syndrome"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria\n\n        Concurrent Medication:\n\n        Allowed:\n\n          -  Prophylaxis with aerosolized pentamidine, topical antifungals, TMP / SMX, dapsone, or\n             isoniazid.\n\n        Patients must have:\n\n          -  HIV infection.\n\n          -  CD4 count 50 - 500 cells/mm3.\n\n          -  Prior AZT use for more than 6 months OR documented intolerance to AZT with more than\n             6 months use of another anti-HIV therapy other than d4T or any protease inhibitor.\n\n          -  No active opportunistic infection or visceral Kaposi's sarcoma.\n\n        NOTE:\n\n          -  Patients with hemophilia may be enrolled at discretion of investigator.\n\n        Exclusion Criteria\n\n        Co-existing Condition:\n\n        Patients with the following symptoms or conditions are excluded:\n\n          -  Symptomatic neuropathy.\n\n          -  Acute hepatitis.\n\n        Concurrent Medication:\n\n        Excluded:\n\n          -  Antiretrovirals other than specified in protocol.\n\n          -  Chronic therapy for an active opportunistic infection.\n\n          -  Immunosuppressive therapy.\n\n        Prior Medication:\n\n        Excluded:\n\n          -  Any prior protease inhibitor or d4T.\n\n          -  Any nucleoside analogs within 2 weeks prior to study entry.\n\n          -  Investigational agents or immunomodulators within 30 days prior to study entry.\n\n        Required:\n\n          -  More than 6 months of prior AZT unless intolerant, in which case more than 6 months\n             of another anti-HIV therapy (other than protease inhibitors or d4T)."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "60 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": "540", 
        "firstreceived_date": "November 2, 1999", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT00002354", 
            "org_study_id": "246D", 
            "secondary_id": "37"
        }, 
        "intervention": [
            {
                "intervention_name": "Indinavir sulfate", 
                "intervention_type": "Drug"
            }, 
            {
                "intervention_name": "Stavudine", 
                "intervention_type": "Drug"
            }
        ], 
        "intervention_browse": {
            "mesh_term": [
                "HIV Protease Inhibitors", 
                "Indinavir", 
                "Stavudine"
            ]
        }, 
        "keyword": [
            "Drug Therapy, Combination", 
            "Acquired Immunodeficiency Syndrome", 
            "AIDS-Related Complex", 
            "Stavudine", 
            "HIV Protease Inhibitors", 
            "Indinavir"
        ], 
        "lastchanged_date": "June 23, 2005", 
        "location": {
            "facility": {
                "address": {
                    "city": "Whitehouse Station", 
                    "country": "United States", 
                    "state": "New Jersey", 
                    "zip": "088890100"
                }, 
                "name": "Merck & Co Inc"
            }
        }, 
        "location_countries": {
            "country": "United States"
        }, 
        "official_title": "One Year Study in HIV-1 Seropositive, AZT-Experienced Patients to Evaluate the Safety and Efficacy of MK-639 Administered Concomitantly With Stavudine (d4T)", 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration"
        }, 
        "phase": "N/A", 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT00002354"
        }, 
        "source": "NIH AIDS Clinical Trials Information Service", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Merck Sharp & Dohme Corp.", 
                "agency_class": "Industry"
            }
        }, 
        "study_design": "Endpoint Classification: Safety Study, Masking: Double-Blind, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "January 1996"
    }, 
    "geocoordinates": {
        "Merck & Co Inc": "40.617 -74.77"
    }
}